Juvenile idiopathic arthritis combined with atopic dermatitis: choice of therapy

Read full text Summarise with VIRAT
Authors: Elena Borisovna Tyurina, Посевина Анастасия Николаевна, S. V. Maltsev, O. A. Borodina
Cited by: 0
References: 7

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

A rare clinical case of a combined diagnosis in a child is presented, which demonstrates the difficulty of choosing a genetically engineered biological therapy for two severe disabling diseases in one patient. The initial clinical picture of the child included manifestations of atopic dermatitis from an early age, followed by the addition of joint syndrome at school age, which made it difficult to treat both diseases. A single option for immunosuppressive therapy of both competing diseases was considered in the form of prescribing methotrexate. During the examination and dynamic monitoring of the patient, it was decided to initiate therapy with a genetically engineered biological drug from the TNF-α inhibitor group. A special feature of this clinical case is the trajectory of the therapeutic search. Etanercept therapy proved to be effective, quickly relieving the joint syndrome and reducing the severity of the skin syndrome. Regular use of the drug made it possible to achieve stable stabilization of the child's condition and prevent the development of complications of the combined disease. This case highlights the need for high vigilance regarding the combination of these diseases, as well as the importance of choosing the right treatment and starting it on time.

Fields of Study & Subjects

Autoimmune and Inflammatory Disorders Research Rheumatoid Arthritis Research and Therapies Dermatology and Skin Diseases

Publication details

Journal / source
Medical Herald of the South of Russia
Volume
17
Issue
1
Pages
52–56
Publication date
26 March 2026
Language
EN